Klein Janet D, Rash Arjun, Sands Jeff M, Ecelbarger Carolyn M, Tiwari Swasti
School of Medicine, Renal Division, Emory University, 1639 Pierce Drive NE, Atlanta, GA, 30322, USA.
J Epithel Biol Pharmacol. 2009 Jan 1;2(7):23. doi: 10.2174/1875044300902010023.
Diabetes is associated with an activated renal renin-angiotensin-aldosterone system (RAAS) and it was shown that streptozotocin (STZ)-induced diabetic rats had increased whole kidney protein levels of the epithelial sodium channel subunits (α-, β- and γ-ENaC). However, the role of the RAAS on the regional, i.e., cortical versus medullary, regulation of ENaC is unclear. Male Sprague-Dawley rats were injected with STZ (intravenous, 65 mg/kg·bw, n=12/group). After 14 days, half of them received drinking water with candesartan (2 mg/kg·bw/day), an angiotensin-II type-1 receptor (AT1R) antagonist, for one week. In the medulla, i.e., inner stripe of the outer medulla (ISOM), base and/or tip of the inner medulla, immunoblotting revealed increased protein abundances of α1 Na-K-ATPase and ENaC subunits with diabetes (200-600% of controls), which were not reversed by candesartan. In fact, candesartan increased all ENaC subunits and α1 Na-K-ATPase in the ISOM and/or base in control rats. In contrast, in the cortex, diabetes did not increase these proteins. However, candesartan reduced cortical β- and γ-ENaC regardless of diabetic state. In summary, diabetes-induced increases in ENaC were seen preferentially in the medulla. These changes appeared to be due to a mechanism clearly distinct from AT1R activation, because they were not abolished by candesartan. In fact, candesartan treatment tended to increase some of these medullary proteins, perhaps in compensation for increased NaCl load. In contrast, cortical β- and γ-ENaC were reduced by candesartan regardless of diabetic state suggesting their regulation by AT1R at this site; however this did not appear to be a site of diabetes-induced ENaC up-regulation.
糖尿病与肾脏肾素-血管紧张素-醛固酮系统(RAAS)激活相关,并且有研究表明链脲佐菌素(STZ)诱导的糖尿病大鼠全肾上皮钠通道亚基(α-、β-和γ-ENaC)的蛋白水平升高。然而,RAAS对ENaC的区域调节作用,即皮质与髓质的调节作用尚不清楚。将雄性Sprague-Dawley大鼠静脉注射STZ(65 mg/kg体重,每组n = 12只)。14天后,其中一半大鼠饮用含坎地沙坦(2 mg/kg体重/天)的水,坎地沙坦是一种血管紧张素II 1型受体(AT1R)拮抗剂,持续一周。在髓质,即外髓质内带(ISOM)、内髓质基部和/或尖端,免疫印迹显示糖尿病时α1钠钾ATP酶和ENaC亚基的蛋白丰度增加(为对照组的200 - 600%),坎地沙坦不能使其逆转。实际上,坎地沙坦使对照组大鼠ISOM和/或基部的所有ENaC亚基和α1钠钾ATP酶增加。相反,在皮质,糖尿病并未使这些蛋白增加。然而,无论糖尿病状态如何,坎地沙坦均可降低皮质β-和γ-ENaC。总之,糖尿病诱导的ENaC增加主要见于髓质。这些变化似乎是由于一种明显不同于AT1R激活的机制引起的,因为它们未被坎地沙坦消除。实际上,坎地沙坦治疗倾向于增加一些髓质蛋白,可能是为了补偿增加的NaCl负荷。相反,无论糖尿病状态如何,坎地沙坦均可降低皮质β-和γ-ENaC,提示它们在此部位受AT1R调节;然而这似乎不是糖尿病诱导ENaC上调的部位。